Semaglutide shows sustained weight loss benefits in older adults

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

Pooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 years

A new analysis of the STEP trials carried out by semaglutide manufacturer Novo Nordisk has analyzed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations. The study is by Prof Luca Busetto from the University of Padova in Italy and colleagues, including those from Novo Nordisk.

Novo Nordisk Shares Rise As Ozempic Study Shows 15% Weight Loss In Older Adults

A pooled analysis found semaglutide 2.4 mg led to 15.4% weight loss in adults 65 and older after 68 weeks, compared to 5.1% for placebo. Novo Nordisk B shares rose 3.75% to 301.20 crowns in Copenhagen. The analysis included 358 participants from multiple STEP trials. Novo is seeking to defend its obesity drug franchise as competition with Eli Lilly intensifies. The post Novo Nordisk Shares Rise As Ozempic Study Shows 15% Weight Loss In Older Adu…